These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 28931682

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Inhibition of human endogenous retrovirus-K by antiretroviral drugs.
    Tyagi R, Li W, Parades D, Bianchet MA, Nath A.
    Retrovirology; 2017 Mar 22; 14(1):21. PubMed ID: 28330477
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
    Nitanda T, Wang X, Somekawa K, Yuasa S, Baba M.
    Antivir Chem Chemother; 2001 May 22; 12(3):161-7. PubMed ID: 12959324
    [Abstract] [Full Text] [Related]

  • 7. Human Endogenous Retrovirus Type K (HERV-K) Particles Package and Transmit HERV-K-Related Sequences.
    Contreras-Galindo R, Kaplan MH, Dube D, Gonzalez-Hernandez MJ, Chan S, Meng F, Dai M, Omenn GS, Gitlin SD, Markovitz DM.
    J Virol; 2015 Jul 22; 89(14):7187-201. PubMed ID: 25926654
    [Abstract] [Full Text] [Related]

  • 8. New developments in anti-HIV chemotherapy.
    De Clercq E.
    Curr Med Chem; 2001 Nov 22; 8(13):1543-72. PubMed ID: 11562282
    [Abstract] [Full Text] [Related]

  • 9. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S.
    Antivir Chem Chemother; 2003 Jan 22; 14(1):49-59. PubMed ID: 12790516
    [Abstract] [Full Text] [Related]

  • 10. New developments in anti-HIV chemotherapy.
    De Clercq E.
    Biochim Biophys Acta; 2002 Jul 18; 1587(2-3):258-75. PubMed ID: 12084468
    [Abstract] [Full Text] [Related]

  • 11. Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors.
    Qari SH, Magre S, García-Lerma JG, Hussain AI, Takeuchi Y, Patience C, Weiss RA, Heneine W.
    J Virol; 2001 Jan 18; 75(2):1048-53. PubMed ID: 11134319
    [Abstract] [Full Text] [Related]

  • 12. New anti-HIV agents and targets.
    De Clercq E.
    Med Res Rev; 2002 Nov 18; 22(6):531-65. PubMed ID: 12369088
    [Abstract] [Full Text] [Related]

  • 13. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
    Albright AV, Erickson-Viitanen S, O'Connor M, Frank I, Rayner MM, González-Scarano F.
    AIDS Res Hum Retroviruses; 2000 Oct 10; 16(15):1527-37. PubMed ID: 11054266
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP, Nandy P, Avramis VI.
    In Vivo; 2000 Oct 10; 14(3):377-88. PubMed ID: 10904870
    [Abstract] [Full Text] [Related]

  • 15. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 10; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
    Limoges J, Persidsky Y, Poluektova L, Rasmussen J, Ratanasuwan W, Zelivyanskaya M, McClernon DR, Lanier ER, Gendelman HE.
    Neurology; 2000 Jan 25; 54(2):379-89. PubMed ID: 10668699
    [Abstract] [Full Text] [Related]

  • 17. Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
    Shi M, Wang X, De Clercq E, Takao S, Baba M.
    Antimicrob Agents Chemother; 2007 Jul 25; 51(7):2600-4. PubMed ID: 17470654
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W.
    Antivir Ther; 2004 Feb 25; 9(1):57-65. PubMed ID: 15040537
    [Abstract] [Full Text] [Related]

  • 19. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R, Yokoyama M, Sato H, Reilly C, Mansky LM.
    J Virol; 2005 Sep 25; 79(18):12045-57. PubMed ID: 16140780
    [Abstract] [Full Text] [Related]

  • 20. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J, De Clercq E, Carbonez A, Burt V, Kleim JP.
    AIDS Res Hum Retroviruses; 2000 Apr 10; 16(6):517-28. PubMed ID: 10777142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.